Malignant Pleural Mesothelioma Market Forecast and Trends
The global Malignant Pleural
Mesothelioma market has reached USD Billion in 2019 and estimated to reach USD
Billion in 2026 and anticipated to grow by CAGR of 7.6% during the forecast
period 2020-2026. The global market for malignant pleural mesothelioma will
likely incur a favorable boost from increased healthcare spending seen in
multiple parts of the world, coupled with the availability of better treatment
prognosis for malignant pleural mesothelioma. Overall, the global malignant
mesothelioma market is also seeing increased adoption of combination therapies.
In the treatment of malignant pleural mesothelioma, many companies promote the
increasing use of chemotherapy and immune-oncology procedures.
Malignant Pleural Mesothelioma Market: Overview
mesothelioma is a rare and aggressive cancer that develops around the lungs in
a thin layer of tissue called pleura. The microscopic inhalation of asbestos
fibers causes malignant pleural mesothelioma. Once the person is inhaling
asbestos particles, the human body fails to remove asbestos needle-like fibers
from the lungs. The incidence of
malignant pleural mesothelioma in Europe is around 20 per million inhabitants,
according to the NIH, and it is increasing globally. This will then require the
need to develop innovative treatments for malignant pleural mesothelioma, which
will drive market growth. Malignant pleural mesothelioma signs include dyspnea,
recurrent dry or raspy cough, chest pain, difficulty swallowing, also known as
dysphagia, and also known as hemoptysis, coughing up the blood. Since the mid
20th century, the occurrence of Malignant pleural mesothelioma has increased.
The appearance of malignant pleural mesothelioma within and between nations is
Rising exposure to asbestos
People exposed to asbestos
are at a higher risk of developing malignant pleural mesothelioma. Within
contaminated areas, the chance of malignant pleural mesothelioma is increased
by 2 to 10 fold as compared with non-polluted areas. Besides, people exposed to
a high dose of radiation, zeolites (minerals chemically associated with
asbestos), and suffering from simian virus 40 are at risk of developing
malignant pleural mesothelioma and indirectly contribute to the global market
for malignant pleural mesothelioma with the significant growth rate.
Increasing expenditure on
R&D coupled with increasing pipeline molecule
The therapeutic pipeline is
expected to see significant growth in the forthcoming years on the market for
malignant pleural mesothelioma due to higher incidence rates, increased air
pollution, increased geriatric population, and increased healthcare
expenditure. In addition, the advancement of innovative therapy and the launch
of advanced treatment options are likely to provide the malignant pleural
mesothelioma market with lucrative growth opportunities over the 2020-2026
Delay in Diagnosis
The key factor expected to
hamper the growth of the global market for malignant pleural mesothelioma is a
long latent period between onset and symptom, lack of effective treatment, and
low surveillance rates over the 202-2026 forecast period.
Malignant Pleural Mesothelioma Market: Drug Class
Based on drug class, the
global malignant pleural mesothelioma market segmented into Premetrexed and
Combination, Cisplatin and Combination, Carboplatin and Combination,
Gemcitabine, and Combination, Vinorelbine and Combination and Other
Combination. Among the group is considered a combination of pemetrexed and
cisplatin as the normal first-line treatment of malignant pleural mesothelioma.
It is the most effective treatment for Chemotherapy. In a recent study to test
cisplatin and pemetrexed called Mesothelioma Avastin Cisplatin Pemetrexed Trial
(MAPS), the addition of bevacizumab showed significantly improved survival
rates for patients with minimal side effects of malignant pleural mesothelioma.
Malignant Pleural Mesothelioma Market: Distribution Channel
Based on Distribution
Channel, the market is diversified as hospital pharmacies, retail pharmacies,
and oncology centers. Amidst the category oncology centers expected to cater
global malignant pleural mesothelioma market with a high growth rate. Followed
by oncology centers, hospital pharmacies, and retail pharmacies anticipated to
witness significant growth rate during the forecast period of 2020-2026.
Malignant Pleural Mesothelioma Market: Regional Insights
Global Malignant Pleural
Mesothelioma market segmented into five regions, including North America,
Europe, Asia-Pacific, Latin America, and Middle East & Africa. North
America is leading the market for malignant pleural mesothelioma, followed by
Europe due to higher incidence and prevalence rates, an increase in the
geriatric population, and increased demand advance therapy. The Asia Pacific is
an emerging market for malignant pleural mesothelioma due to the development of
healthcare infrastructure, patient awareness, and increased government spending
in the healthcare sector. Low recognition of patients, lack of proper care, and
high therapy costs are factors that narrow the Middle East & Africa market
for malignant pleural mesotheliomas.
Pleural Mesothelioma: Competitive Landscape
Mesothelioma market is fragmented owing to the presence of number of
large-sized companies that hold the majority share of AstraZeneca Plc.,
Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc.,
Novartis AG, Pfizer Inc., Sanofi, Eli Lilly and Company, Teva Pharmaceuticals,
Boehringer Ingelheim GmbH, Mylan N.V., Fresenius Kabi AG, Sun Pharmaceuticals
Industries Ltd, Corden Pharma International GmbH, Concordia International Corp
and Other Prominent Players.
objective of the Study:
To analyze and forecast the
global market size of the Malignant Pleural Mesothelioma.
Analyzing careful market
segmentation and estimating value-based market size through region-based
The global Malignant Pleural
Mesothelioma is divided into five regions: North America, Europe, Asia-Pacific,
Middle East & Africa, Latin America.
To outline, categorize, and
forecast the global AI in the agricultural market based on drug class, route of
administration, and distribution channel with the region.
To examine competitive
developments in the global Malignant Pleural Mesothelioma market, such as
technological advancement, services, and regulatory framework.
To emphasize the impact
study of market dynamics variables such as users, constraints, opportunities,
Profiling key players
strategically and analyzing their market shares comprehensively, together with
detailing the competitive environment for market leaders.
of the Report:
Historical data – 2016-2019
Base Year – 2019
Forecast – 2020 – 2026
Revenue in USD Million/Billion
U.S, Canada, Germany, UK, France, Italy, Spain, Brazil, Mexico,
Argentina, Japan, South Korea, China, India, UAE, South Africa, Saudi Arabia
By Drug Class, Route of Administration, and Distribution
AstraZeneca Plc., Bristol-Myers Squibb Company, F. Hoffmann-La
Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Eli
Lilly and Company, Teva Pharmaceuticals, Boehringer Ingelheim GmbH, Mylan NV,
Fresenius Kabi AG, Sun Pharmaceuticals Industries Ltd, Corden Pharma
International GmbH, Concordia International Corp, Other Prominent Players.
By Drug Class
Pemetrexed and Combination
Cisplatin and Combination
Carboplatin and Combination
Gemcitabine and Combination
Vinorelbine and Combination
By Route of Administration
By Distribution Channel
Middle East & Africa
Questions Answer by the Report
How will the market drivers,
restraints, and opportunities affect the market dynamics?
What will be the market size
in terms of value and volume and market statistics with a detailed classification?
Which segment dominates the
market or region, and one will be the fastest-growing, and why?
A comprehensive survey of
the competitive landscape and the market participant players
Analysis of strategy adopted
by the key player and their impact on other players.
Scope for the Client
Client satisfaction is our
first and last priority, and that’s why BlueWeave Consulting offers
customization according to Company’s specific needs. The following
customization options are available for the report:
With five additional company
Additional country analysis
Detailed segment analysis